Fifty-Five Cases Against Pharmaceutical Company Centralized in New Jersey Court

Fifty-five cases filed against Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, have been approved for centralization in a single New Jersey federal court. The cases—which come from other states such as West Virginia, Kentucky, Illinois, and others—allege that Janssen Pharmaceuticals improperly marketed the drug and failed to warn consumers about its potential dangers. The Judicial Panel for Multidistrict Litigation found that all of the cases share a common issue of fact, and that the drug causes kidney failure and diabetic ketoacidosis, a medical condition caused by acid buildup in the blood.

All materials and information on this web site are presented for informational purposes only. Nothing contained on this site is intended to constitute legal advice. While every effort is made to ensure accuracy of the material and information provided, no guarantee is made regarding its accuracy. No reliance should be made upon the information contained in this site without first seeking the advice of qualified counsel. No attorney-client relationship is established by the use of, or reliance upon, the materials or information contained on this site. While any information you may submit to our firm, once received, will be treated as confidential, any inquiry made by e-mail or by submission of written inquiry, online or otherwise, does not establish an attorney-client relationship. An attorney-client relationship with our firm may only be established via written retainer agreement, executed by a member of our Firm.